Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study

Summary

There is a lack of consensus on the value of detecting and treating symptomatic isolated distal deep-vein thrombosis (DVT) of the lower limbs. In our study, we compared the risk factors and outcomes in patients with isolated symptomatic distal DVT with those with proximal symptomatic DVT. We analysed the data of patients with objectively confirmed symptomatic isolated DVT enrolled in the national (France), multicenter, prospective OPTIMEV study.This sub-study outcomes were recurrent venous thromboembolism, major bleeding and death at three months. Among the 6141 patients with suspicion of isolated DVT included between November 2004 and January 2006, DVT was confirmed in 1643 patients (26.8%). Isolated distal DVT was more frequent than proximal DVT (56.8% vs. 43.2%, respectively; p=0.01). Isolated distal DVT was significantly more often associated with transient risk factors (recent surgery, recent plaster immobilisation, recent travel), whereas proximal DVT was significantly more associated with more chronic states (active cancer, congestive heart failure or respiratory insufficiency, age >75 years). Most patients (96.8%) with isolated distal DVT received anticoagulant therapies.There was no difference in the percentage of recurrent venous thromboembolism and major bleeding in patients with proximal DVT and isolated distal DVT. However, the mortality rate was significantly higher (p<0.01) in patients with proximal DVT (8.0%) than in those with isolated distal DVT (4.4%). Symptomatic isolated distal DVT differs from symptomatic proximal DVT both in terms of risk factors and clinical outcome. Whether these differences should influence the clinical management of these two events remains to be determined.

Keywords

Calf vein thrombosis - distal deep-vein thrombosis - mortality - proximal deep-vein thrombosis - ultrasonography

• References

• 1 Schellong SM. Distal DVT: worth diagnosing? Yes. J Thromb Haemost 2007; 05 (Suppl. 01) 51-54.
• 2 Righini M. Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost 2007; 05 (Suppl. 01) 55-59.
• 3 Righini M, Paris S, Le Gal G. et al. Clinical relevance of Distal deep vein thrombosis. Review of literature data. Thromb Haemost 2006; 95: 56-64.
• 4 Landefeld CS. Noninvasive diagnosis of deep vein thrombosis. JAMA 2008; 300: 1696-1697.
• 5 Kearon C, Kahn S, Agnelli G. et al. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, Jun 2008; 133: 454S-545S.
• 6 Nicolaides AN, Fareed J, Kakkar AK. Prevention and treatment of venous thromboembolism. International Consensus Statement. (Guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.
• 7 Pinede L, Ninet J, Duhaut P. et al. For the Investigators of the “Durée Optimale du Traitement AntiVitamines K” (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of Proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-2460.
• 8 Sevestre MA, Labarere J, Brin S. et al. Optimizing history taking for evaluating the risk of venous thromboembolism: the OPTIMEV study. J Mal Vasc 2005; 30: 217-227.
• 9 Elias A, Mallard L, Elias M. et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs. Thromb Haemost 2003; 89: 221-227.
• 10 Stein PD, Fowler SE, Goodman LR. et al. For the PIOPED II Investigators. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006; 354: 2317-2327.
• 11 The PIOPED Investigators. Value of the ventilation/ perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753-2759.
• 12 Seinturier C, Bosson JL, Colonna M. et al. Site and clinical outcome of deep vein thrombosis of the lower limbs: an epidemiological study. J Thromb Haemost 2005; 03: 1362-1367.
• 13 Vaitkus PT, Leizorovicz A, Cohen AT. et al. PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005; 93: 76-79.
• 14 Meissner MH, Caps MT, Bergelin RO. et al. Early outcome after isolated calf vein thrombosis. J Vasc Surg 1997; 26: 749-756.
• 15 Monreal M, Kakkar AK, Caprini JA. et al. For the RIETE Investigators. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients: findings from the RIETE registry. J Thromb Haemost 2004; 02: 1892-1898.
• 16 Palareti G, Agnelli G, Imberti D. et al. For the MASTER investigators. A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. Thromb Haemost 2008; 99: 241-244.
• 17 Bernardi E, Camporese G, Büller HR. et al. For the Erasmus Study Group. Serial 2-point ultrasonography plus D-dimer vs whole-leg colour-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 2008; 300: 1696-1697.
• 18 Oger E. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Incidence of venous thromboembolism: a community based study in Western France. Thromb Haemost 2000; 83: 657-660.
• 19 Schellong SM, Schwarz T, Halbritter K. et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003; 89: 228-234.
• 20 Büller HR, Davidson BL, Decousus H. et al. For the Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
• 21 Fiessinger JN, Huisman MV, Davidson BL. et al. For the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-689.
• 22 Chong BH, Brighton TA, Baker RI. et al. For the ASTH DVT Study Group. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005; 19: 173-181.
• 23 van Gogh Investigators, Buller HR, Cohen AT. et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
• 24 Bloemenkamp KW, Rosendaal FR, Büller HR. et al. Risk of venous thrombosis with use of current lowdose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65-70.